Lawrence Saperstein, MD
Associate Professor of Radiology and Biomedical ImagingCards
About
Research
Publications
2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease coursePD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2022
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. Journal Of Clinical Oncology 2022, 40: 5024-5024. DOI: 10.1200/jco.2022.40.16_suppl.5024.Peer-Reviewed Original ResearchHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9PET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusMetastatic PCaRadical prostatectomyCT uptakeClinical trialsProstate cancerLesion locationCentral readersNegative lesionsPiflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.
Gorin M, Rowe S, Pienta K, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Stambler N, Siegel B, Morris M. Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. Journal Of Clinical Oncology 2022, 40: 35-35. DOI: 10.1200/jco.2022.40.6_suppl.035.Peer-Reviewed Original ResearchHigh-risk PCaBaseline PSAGleason scoreVolume of interestAverage SUVProstate-specific membrane antigen (PSMA) PET/CTSpecific Membrane Antigen PET/CTBaseline PSA levelsGS 9Prostate cancer patientsPET/CTSUV resultsPelvic lymphadenectomyPSA levelsInitial stagingDisease recurrenceProspective studyBiopsy statusCancer patientsMetastatic PCaRadical prostatectomyClinical trialsCT uptakeLesion locationCentral readers
2021
PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients
Liu H, Yousefi H, Mirian N, Lin M, Menard D, Gregory M, Aboian M, Boustani A, Chen M, Saperstein L, Pucar D, Kulon M, Liu C. PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 766-770. PMID: 37284026, PMCID: PMC10241407, DOI: 10.1109/trpms.2021.3131999.Peer-Reviewed Original Research
Clinical Care
Overview
Lawrence Saperstein, MD, is a specialist in nuclear medicine, which uses small amounts of radioactive substances to create detailed images that help guide treatment decisions and track patient progress.
Dr. Saperstein uses precise, targeted imaging methods to diagnose and treat a range of conditions throughout the body. His expertise in multiple imaging modalities allows for early detection of abnormalities in organs like the thyroid and bones, facilitating timely and effective intervention.
As an associate professor of radiology and biomedical imaging at Yale School of Medicine, Dr. Saperstein is involved in research aimed at enhancing molecular imaging technologies, with the goal of advancing diagnostic capabilities in areas such as prostate cancer detection.
Dr. Saperstein completed his medical training at Duke University School of Medicine. He then pursued an internship in general surgery at Stanford University Medical Center, followed by a residency in diagnostic radiology and a fellowship in nuclear radiology at Columbia Presbyterian Medical Center.
Clinical Specialties
Nuclear Medicine
Fact Sheets
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineGastrointestinal Cancers
Learn More on Yale Medicine
Board Certifications
Nuclear Medicine
- Certification Organization
- AB of Nuclear Medicine
- Latest Certification Date
- 2013
- Original Certification Date
- 2011
Diagnostic Radiology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2000
Yale Medicine News
News
News
- January 18, 2021
Radiologists Bring New Molecular Imaging Technology to Yale
- August 22, 2019
Yale Radiologists Advance Prostate Cancer Imaging
- May 09, 2019
2019 Honors & Achievements
- January 22, 2019
Imaging Agent Shows Promise for Better Prostate Cancer Detection
Get In Touch
Contacts
Mailing Address
Radiology & Biomedical Imaging
PO Box 208042
New Haven, CT 06520-8042
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.